Compare CC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CC | SYRE |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2014 | 2015 |
| Metric | CC | SYRE |
|---|---|---|
| Price | $17.04 | $43.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $16.13 | ★ $56.50 |
| AVG Volume (30 Days) | ★ 3.2M | 573.5K |
| Earning Date | 05-24-2026 | 05-19-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,638,000,000.00 | N/A |
| Revenue This Year | $3.34 | N/A |
| Revenue Next Year | $4.03 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $9.13 | $10.91 |
| 52 Week High | $21.85 | $38.16 |
| Indicator | CC | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 72.37 |
| Support Level | $19.65 | $34.96 |
| Resistance Level | $21.43 | $37.98 |
| Average True Range (ATR) | 1.37 | 2.11 |
| MACD | -0.03 | 0.56 |
| Stochastic Oscillator | 40.00 | 98.33 |
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.